认知行为治疗在预防卒中相关失眠中的有效性研究

注册号:

Registration number:

ChiCTR2000035316 

最近更新日期:

Date of Last Refreshed on:

2020-08-10 10:41:03 

注册时间:

Date of Registration:

2020-08-08 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

认知行为治疗在预防卒中相关失眠中的有效性研究

Public title:

The effect of Cognitive Behavioral Therapy on post stroke insomnia prevention: a randomized controlled trial.

注册题目简写:

English Acronym:

研究课题的正式科学名称:

认知行为治疗在预防卒中相关失眠中的有效性研究

Scientific title:

The effect of Cognitive Behavioral Therapy on post stroke insomnia prevention

研究课题代号(代码):

Study subject ID:

20203357015

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

胡诗雨 

研究负责人:

胡诗雨 

Applicant:

Shiyu Hu 

Study leader:

Shiyu Hu 

申请注册联系人电话:

Applicant telephone:

+86 15007553360

研究负责人电话:

Study leader's
telephone:

+86 15007553360

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

15007553360@163.com

研究负责人电子邮件:

Study leader's E-mail:

15007553360@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

深圳市福田区笋岗西路3002

研究负责人通讯地址:

深圳市福田区笋岗西路3002

Applicant address:

3002 Sungang Road West, Futian District, Shenzhen, China

Study leader's address:

3002 Sungang Road West, Futian District, Shenzhen, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

深圳市第二人民医院

Applicant's institution:

Shenzhen Second People's Hospital

研究负责人所在单位:

深圳市第二人民医院

Affiliation of the Leader:

Shenzhen Second People's Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

20200601019-FS01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

深圳市第二人民医院临床科研伦理委员会

Name of the ethic committee:

Clinical Research Ethics Committee of Shenzhen Second People's Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2020-07-02 00:00:00

伦理委员会联系人:

陈旭红

Contact Name of the ethic committee:

Xuhong Chen

伦理委员会联系地址:

深圳市福田区笋岗西路3002号

Contact Address of the ethic committee:

3002 Sungang Road West, Futian District, Shenzhen, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

深圳市第二人民医院

Primary sponsor:

Shenzhen Second People's Hospital

研究实施负责(组长)单位地址:

深圳市福田区笋岗西路3002

Primary sponsor's address:

3002 Sungang Road West, Futian District, Shenzhen, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东

市(区县):

深圳

Country:

China

Province:

Guangdong

City:

Shenzhen

单位(医院):

深圳市第二人民医院

具体地址:

福田区笋岗西路3002

Institution
hospital:

Shenzhen Second People's Hospital

Address:

3002 Sungang Road West, Futian District

经费或物资来源:

院内经费

Source(s) of funding:

Funds of hospital

研究疾病:

卒中相关性失眠  

Target disease:

Stroke related insomnia

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

评价急性缺血性患者中,CBTI干预对照常规睡眠健康教育,发病3个月内的卒中相关失眠发生率的差异。  

Objectives of Study:

To evaluate the differences in the incidence of insomnia within 3 months after onset of acute ischemic stroke between CBTI intervention and routine sleep health education.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1. 颅脑CT或MR诊断为脑出血或其他脑部疾病,例如颅内肿瘤、脓肿、代谢性脑病等;
2. 仅存在单独的视力改变、单独的感觉症状(如麻木感)、单独的头晕或眩晕,颅脑影像学检查(CT 或 MRI)没有急性缺血性脑卒中证据;
3. 发病mRS评分>2分;
4. 本次急性缺血性卒中病情严重导致需长期卧床患者或NIHSS评分>14分;
5. 本次急性缺血性脑卒中发病7天后仍需进行持续心电监护患者;
6. 未来 3 个月内计划或可能进行任何形式的手术患者;
7. 既往确诊焦虑或抑郁障碍,正在或需要长期服用抗焦虑/抑郁药物患者;
8. 既往存在难治性失眠,需要长期服用药物辅助睡眠患者;
9. 妊娠或有妊娠计划的育龄期女性,以及哺乳期女性
10. 恶性肿瘤患者或患有其他严重非心脑血管疾病,预期生存时间小于3个月;
11. 30天内参加过其他临床药物或者器械研究;
12. 因严重认知障碍、精神疾患无法理解和/或服从CBTI干预和/或随访。

Exclusion criteria:

1. CT or MR diagnosis of cerebral hemorrhage or other brain diseases, such as intracranial tumors, abscesses, metabolic encephalopathy, etc.
2. There were only separate visual changes, sensory symptoms (such as numbness), dizziness or vertigo, and no evidence of acute ischemic stroke on brain imaging (CT or MRI).
3. mRS score more than 2.
4. The acute ischemic stroke was so severe that the patient needed to stay in bed for a long time or NIHSS >14.
5. The patient still needs continuous ECG monitoring 7 days after the onset of acute ischemic stroke.
6. Any type of surgery is planned or may be performed in the next three months.
7. Patients who have a prior diagnosis of anxiety or depression disorder, requiring long-term use of anti-anxiety/depression medications.
8. Patients with pre-existing refractory insomnia need to take long-term medication to assist sleep.
9. Women of childbearing age who are pregnant or have planned pregnancy, and women who are breastfeeding.
10. Patients with malignant tumor or other serious non-cardiovascular and cerebrovascular diseases, and the expected life time less than 3 months.
11. Participated in other clinical drug or device studies within 30 days.
12. Inability to understand and/or comply with CBTI intervention and/or follow-up due to severe cognitive impairment, mental disorders.

研究实施时间:

Study execute time:

From 2020-08-01 00:00:00 To 2023-07-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2020-09-15 00:00:00 To 2021-12-31 00:00:00

干预措施:

Interventions:

组别:

试验组

样本量:

123

Group:

experimental group

Sample size:

干预措施:

为失眠认知行为干预

干预措施代码:

Intervention:

Cognitive Behavioral Therapy for insonmia

Intervention code:

组别:

对照组

样本量:

123

Group:

control group

Sample size:

干预措施:

常规睡眠健康教育

干预措施代码:

Intervention:

Routine sleep health education

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广东 

市(区县):

 

Country:

China

Province:

Guangdong

City:

单位(医院):

深圳市第二人民医院 

单位级别:

三级甲等 

Institution
hospital:

Shenzhen Second People's Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

首次发病7天内的急性缺血性患者卒中相关失眠发生情况

指标类型:

主要指标

Outcome:

Stroke related insomnia in acute ischemic patients within 7 days of first onset

Type:

Primary indicator

测量时间点:

发病3月内

测量方法:

阿斯森失眠量表

Measure time point of outcome:

within 3 months

Measure method:

Athens Insomnia Scale, AIS

指标中文名:

卒中相关失眠

指标类型:

次要指标

Outcome:

Stroke related insomnia

Type:

Secondary indicator

测量时间点:

6个月、1年随访时

测量方法:

阿斯森失眠量表

Measure time point of outcome:

6 months and 1 year

Measure method:

Athens Insomnia Scale, AIS

指标中文名:

睡眠质量

指标类型:

次要指标

Outcome:

sleep quality

Type:

Secondary indicator

测量时间点:

3个月、6个月、1年

测量方法:

匹兹堡睡眠质量指数

Measure time point of outcome:

3 months, 6 months and 1 year

Measure method:

Pittsburgh sleep quality index, PSQI

指标中文名:

焦虑障碍

指标类型:

次要指标

Outcome:

Anxiety disorder

Type:

Secondary indicator

测量时间点:

3个月、6个月、1年

测量方法:

汉密尔顿焦虑量表

Measure time point of outcome:

3 months, 6 months and 1 year

Measure method:

Hamilton Anxiety Scale, HAMA

指标中文名:

抑郁障碍

指标类型:

次要指标

Outcome:

Depressive disorder

Type:

Secondary indicator

测量时间点:

3个月、6个月、1年

测量方法:

汉密顿抑郁量表

Measure time point of outcome:

3 months, 6 months and 1 year

Measure method:

Hamilton Depression Scale, HAMD

指标中文名:

神经功能残损情况

指标类型:

次要指标

Outcome:

Neurological impairment

Type:

Secondary indicator

测量时间点:

3个月、6个月、1年

测量方法:

美国国立卫生研究院卒中评分

Measure time point of outcome:

3 months, 6 months and 1 year

Measure method:

National Institute of Health stroke scale, NIHSS

指标中文名:

生活质量

指标类型:

次要指标

Outcome:

Quality of life

Type:

Secondary indicator

测量时间点:

3个月、6个月、1年

测量方法:

欧洲五维健康量表

Measure time point of outcome:

3 months, 6 months and 1 year

Measure method:

EQ-5D

指标中文名:

卒中复发率

指标类型:

次要指标

Outcome:

Recurrence rate of stroke

Type:

Secondary indicator

测量时间点:

3个月、6个月、1年

测量方法:

Measure time point of outcome:

3 months, 6 months and 1 year

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由本项目负责人利用统计学软件进行随机化

Randomization Procedure (please state who generates the random number sequence and by what method):

The statistical software is used for randomization by the principle investigator.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

开放

Blinding:

open-label

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

尚未明确

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

NA

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

纸质版CRF,利用Epidata建立EDC

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Paper CRF, Epidata for EDC

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2020-08-08 16:16:22